ProQR Therapeutics NV
NASDAQ:PRQR

  • LAST PRICE
    3.6200
  • TODAY'S CHANGE (%)
    0.0100 (0.2770%)
  • Bid / Lots
    3.3600/ 102
  • Ask / Lots
    3.8200/ 10
  • Open / Previous Close
    3.6000 / 3.6100
  • Day Range
    3.5700
    3.6800
  • 52 Week Range
    1.1800
    4.6200
  • Volume
    390,089

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 8, 2024

  • Nov 7, 2024

      Show headlines and story abstract

    • 7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: PRQR

    • 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: PRQR
      -- Results related to financial liabilities measured at fair value through profit or loss (139) (117) (266) (1,008) ---------- --------- ---------- --------- -- Income tax expenses -- (83) (197) (83) ---------- --------- ---------- --------- Changes in working capital 1,117 (2,008) (12,721) 46,660 ---------- --------- ---------- --------- Cash (used in) / generated by operations (6,299) (8,393) (29,046) 25,120 ---------- --------- ---------- --------- Corporate income tax received 1 83 197 83 ---------- --------- ---------- --------- Interest received 860 802 2,402 1,667 ---------- --------- ---------- --------- Interest paid (219) -- (598) -- ---------- --------- ---------- --------- Net cash (used in) / generated by operating activities (5,657) (7,508) (27,045) 26,870 ---------- --------- ---------- --------- Cash flow from investing activities Increase in financial asset - current -- -- (17,000) -- ---------- --------- ---------- --------- Decrease in financial asset - current 17,000 -- 17,000 -- ---------- --------- ---------- --------- Purchases of property, plant and equipment (286) (339) (1,285) (769) ---------- --------- ---------- --------- Proceeds from sale of property, plant and equipment -- -- -- 47 ---------- --------- ---------- --------- Net cash generated by / (used in) investing activities 16,714 (339) (1,285) (722) ---------- --------- ---------- --------- Cash flow from financing activities ---------- --------- ---------- --------- Proceeds from exercise of share options 1 151 175 155 ---------- --------- ---------- --------- Repayment of lease liability (454) (432) (1,329) (1,338) ---------- --------- ---------- --------- Net cash used in financing activities (453) (281) (1,154) (1,183) ---------- --------- ---------- --------- Net increase / (decrease) in cash and cash equivalents 10,604 (8,128) (29,484) 24,965 ---------- --------- ---------- --------- Currency effect cash and cash equivalents (173) 118 (40) 812 ---------- --------- ---------- --------- Cash and cash equivalents, at beginning of the period 78,970 128,562 118,925 94,775 ---------- --------- ---------- --------- Cash and cash equivalents at the end of the period 89,401 120,552 89,401 120,552 ---------- --------- ----------

  • Oct 29, 2024

  • Oct 25, 2024

      Show headlines and story abstract

    • 4:45PM ET on Friday Oct 25, 2024 by Dow Jones
      Companies Mentioned: PRQR

      ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

      LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) ("ProQR"), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer(TM) RNA editing technology platform, today announced the closing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the "Offering") at a public offering price of $3.50 per share, for total gross proceeds of $63.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. All of the shares in the Offering were sold by ProQR.

Peers Headlines